Promoter holding
64.27%
CB
Cml Biotech Limited - Due diligence report
A 360° intelligence report on Cml Biotech: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Cml Biotech — 360° Intelligence Report
Generated from MCA filings & public records77/100
Trust Score
Low Risk
Cml Biotech is assessed as Low Risk with a Trust Score of 77/100. Cml Biotech is an active public limited indian non-government company incorporated in 1999, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.
Report generated on 10 Aug 2026 from the latest processed filings. Cml Biotech Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 1.42).
- Profitable - internal accruals available.
Charges position: 14 open (77.67 cr) · 15 satisfied (30.40 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 3 | 48.0 cr |
| Others | 5 | 48.0 cr |
| Sidbi | 10 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
| The South Indian Bank Limited | 7 | 48.0 cr |
| The Federal Bank Limited | 1 | 48.0 cr |
Compliance Score: 88/100 Low Risk
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- 4 active GST registration(s).
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PARAPULLY VARKEY JOSHY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JESSY POULOSE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHWIN PAUL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PAUL SHALINI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ajayaghosh Ayyappan | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHASKARANPILLAI SANTOSHKUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MR PAULOSE JACOB | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| POULOSE CHAKU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: MR PAULOSE JACOB (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Asset base grew 24% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 27+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 0.86 in a year.
14 open charge(s) registered - assets are encumbered.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment52/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 14 open charge(s) of 77.67 cr already registered.
- Compliance record supports lending.
Investor view70/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events18 Jul 2025
Charge satisfied
Axis Bank Limited
30 Sep 2024
Last AGM held
Annual general meeting
23 Sep 2024
Director ceased
Sankaranarayanan Ramanathan
03 May 2024
Director appointed
Ajayaghosh Ayyappan (Director)
31 Mar 2024
Latest balance sheet
Filed with ROC
18 Mar 2024
Director ceased
SUMI JOSHY
Director ceased
AJIN ANTO MADHATHIPARAMBIL
30 Nov 2023
Charge created
Sidbi - 3.16 cr
27 Nov 2023
Charge created
Sidbi - 2.00 cr
29 Sep 2023
Director ceased
BHASKARANPILLAI SANTOSHKUMAR
01 Jun 2023
Director appointed
BHASKARANPILLAI SANTOSHKUMAR (Director)
19 Apr 2023
Charge created
Sidbi - 1.00 cr
01 Mar 2023
Charge created
Sidbi - 4.85 cr
20 Feb 2023
Charge satisfied
Others
29 Sep 2022
Charge created
Hdfc Bank Limited - 15.00 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
8 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Ritika Packaging Private Limited | U74950GA1996PTC002108 | Goa, Goa, India |
| Tti Polymers Private Limited | U25200DL2007PTC168012 | New Delhi, Delhi, India |
| Western Outdoor Structures Private Limited | U45202MH2008PTC179368 | Thane, Maharashtra, India |
| Anantshree Polyfab Private Limited | U25209WB2016PTC215591 | Burdwan Rd Siliguri, West Bengal, India |
| Aultra Paints Private Limited | U24220TG2014PTC093801 | Tirumalagiri, Telangana, India |
| Jai Laxmi Cement Company Private Limited | U26109WB1987PTC042992 | Kolkata, West Bengal, India |
| Rishiroop Polymers Private Limited | U24100MH1989PTC054651 | Mumbai, Maharashtra, India |
| Soriso Ceramic | U26930GJ2006PTC048010 | Dist: Rajkot, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Cml Biotech before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Cml Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Cml Biotech - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Cml Biotech pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Cml Biotech - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Cml Biotech an active company?
Cml Biotech has MCA status “Active” with a compliance score of 88/100 (Low Risk).
Is Cml Biotech financially healthy?
Cml Biotech has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.
Should I do business with Cml Biotech?
Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Cml Biotech?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 8 active director(s) are on record.
Does Cml Biotech have loans or charges against its assets?
14 open charge(s) are registered against its assets, and 15 earlier charge(s) stand satisfied.
Is Cml Biotech up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).
Is it risky to lend to Cml Biotech?
Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
